Chun Wu - Bristol Myers Squibb | 人才画像

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 16 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Topical Sphingosine-1-Phosphate (S1P) Receptor 1 Modulation Regulates Gut Angiogenesis in Inflammatory Bowel Diseases

J. Wang,G. West,S. Lin,P. Mukherjee,R. Maddux,C. Wu,S. Hu,Q. T. Nguyen,D. Czarnecki,H. N. Le,R. Mao,J. Chandra,I. Gordon,A. Petersen,S. Harris,F. Rieder

JOURNAL OF CROHNS & COLITIS (2024): I40-I40

引用0浏览0引用

Ozanimod Differentially Impacts Circulating Lymphocyte Subsets in Patients with Moderately to Severely Active Crohn's Disease

Sarah Harris,Brian G. Feagan,Stephen Hanauer,Severine Vermeire,Subrata Ghosh,Jim Yan,Chun Wu,Yanhua Hu,Rachel Maddux,Douglas C. Wolf,Geert D’Haens

DIGESTIVE DISEASES AND SCIENCES（2024）

引用0浏览0WOS引用

Tu1880 IMPACT OF OZANIMOD (OZA) ON C-X-C MOTIF CHEMOKINE LIGAND 9 (CXCL9) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE (CD): RESULTS FROM THE PHASE 2 STEPSTONE STUDY

Geert D'Haens, Jiangwei Zhang,Subrata Ghosh,Douglas C. Wolf,Brian G. Feagan,Rachel Maddux,Chun Wu,Sarah Hu,AnnKatrin Petersen,Sarah Harris

Gastroenterologyno. 5 (2024): S-1451

引用0浏览0引用

S1133 Impact of Ozanimod on Interleukin-17A Levels and the Association with OZA Efficacy in Patients with Moderately to Severely Active Ulcerative Colitis: Data from the Phase 3 True North Study

Sarah E. Harris,Rachel Maddux,Wu Chun,Yanhua Hu,AnnKatrin Petersen,Séverine Vermeire

The American journal of gastroenterologyno. 10S (2023): S867-S867

引用0浏览0引用

Correlation of Baseline Neuronal Markers With Clinical, Cognitive, Radiological, and Patient-Reported Outcomes in Patients With Early Relapsing Multiple Sclerosis in the Ozanimod ENLIGHTEN Study

Sarah Morrow,Rachel Maddux,Chun Wu, Kai Fu,Jon Riolo,Sarah Harris

MULTIPLE SCLEROSIS JOURNAL (2023): 1109-1109

引用0浏览0引用

Pharmacodynamic Changes in SLE Relevant Gene Expression Induced by Deucravacitinib in Patients Enrolled in the Phase 2 PAISLEY Trial

Chun Wu, Cristina Arriens,J. Michelle Kahlenberg,Yanhua Hu, Coburn Hobar, Adrian Coles, Ian M. Catlett

ARTHRITIS & RHEUMATOLOGY (2023): 2973-2975

引用0浏览0引用

Development of an IFN 5-Gene Signature Score to Identify IFN-high and IFN-low Subsets and As a Pharmacodynamic Biomarker for Deucravacitinib Treatment in a Phase 2 Trial in Patients with Systemic Lupus Erythematosus

Chun Wu,Yanhua Hu,Mary K. Crow,Amit Saxena,Cristina Arriens, Coburn Hobar, Adrian Coles, Ian M. Catlett

ARTHRITIS & RHEUMATOLOGY (2023): 1699-1701

引用0浏览0引用

Nex-T TM Cluster of Differentiation 19 (CD19) Chimeric Antigen Receptor (CAR) T-Cell Therapy BMS-986353 (CC-97540): Comparative Analysis of Baseline Patient Data from Trials in Systemic Lupus Erythematosus (SLE) and Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Related to Manufacturability and Potential Safety

Fabian Mueller,Julie Rytlewski,Chun Wu,Sarah Hu,Ashley Koegel,Nikolay Delev,Ana Kostic,Vaishali Shah,Thomas Wegman,Georg Schett

Bloodno. Supplement 1 (2023): 6873-6873

引用0浏览0引用

S1134 Association of Nonswitched Memory B-Cell (MBC) Levels with Ozanimod (OZA) Efficacy in Patients (pts) with Moderately to Severely Active Crohn’s Disease (CD): Results from the Phase 2 STEPSTONE Study

Sarah Harris,Brian G. Feagan,Stephen B. Hanauer,Severine Vermeire,Subrata Ghosh,Jim Yan,Chun Wu,Yanhua Hu,Rachel Maddux,Douglas C. Wolf,Geert R. D'Haens

The American journal of gastroenterologyno. 10S (2023): S867-S868

引用0浏览0引用

S876 Efficacy of Deucravacitinib, an Oral, Selective, TYK2 Inhibitor, in Patients with Moderately to Severely Active Ulcerative Colitis and Prior Exposure to Biologic Therapy: Subanalysis from the Phase 2 LATTICE-UC Study

Stefan Schreiber,Nick Powell,Florian Rieder,Anita Afzali, Yi Lou,Mark Osterman,Chun Wu,Lisu Wang,Courtney Radosti,Aditya Patel

The American Journal of Gastroenterologyno. 10S (2022): e632-e633

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn